11 Result(s)
within
Shigeo Masuda
English
-
Article
Open AccessSafety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
The safety, efficacy, and pharmacokinetics of copanlisib were evaluated in this phase Ib/II study in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). The primary endpoint was saf...
-
Article
Expandable progenitors from induced pluripotent stem cells
-
Article
Open AccessTeratocarcinomas Arising from Allogeneic Induced Pluripotent Stem Cell-Derived Cardiac Tissue Constructs Provoked Host Immune Rejection in Mice
Transplantation of induced pluripotent stem cell-derived cardiac tissue constructs is a promising regenerative treatment for cardiac failure: however, its tumourigenic potential is concerning. We hypothesised ...
-
Article
Open AccessEliminating residual iPS cells for safety in clinical application
-
Article
CD30-targeting immunoconjugates and bystander effects
-
Article
Emerging innovation towards safety in the clinical application of ESCs and iPSCs
-
Article
A recipe for targeted therapy in prostate cancer
-
Article
Modelling Fanconi anemia pathogenesis and therapeutics using integration-free patient-derived iPSCs
Fanconi anaemia (FA) is a recessive disorder characterized by genomic instability, congenital abnormalities, cancer predisposition and bone marrow (BM) failure. However, the pathogenesis of FA is not fully und...
-
Article
Niche-less maintenance of HSCs by 2i
Maintenance of hematopoietic stem cells (HSCs) in vitro has been believed to be difficult due to a lack of complete understanding of HSC quiescence maintained by the niche. Recent evidence suggests that in vitro ...
-
Article
In vitro generation of platelets through direct conversion: first report in My Knowledge (iMK)
Blood transfusion medicine requires a constant supply of platelets, which is now totally donor dependent. Recent advances in the generation of platelets in vitro through megakaryocytes (MKs) may provide protocols...
-
Article
The microenvironment and resistance to personalized cancer therapy
